Inmed Pharmaceuticals Inc. (INM) Stock Price & Analysis
Inmed Pharmaceuticals Inc. (INM) fell 0.65% to USD 1.53 as of June 10, 2026 at 03:31 UTC, according to Nexqual real-time market data.
INM last closed at USD 1.54; the session ranged USD 1.48–1.55 on volume of 67,754 shares. Market capitalization is $5.07M, with a 52-week range of USD 0.58–5.5 (NCM). Source: Nexqual, June 10, 2026 at 03:31 UTC.
Key Statistics (as of June 10, 2026 at 03:31 UTC)
| Price | USD 1.53 |
|---|---|
| Change | ▼ 0.65% (down) |
| Previous Close | USD 1.54 |
| Open | USD 1.53 |
| Day Range | USD 1.48 – 1.55 |
| 52-Week Range | USD 0.58 – 5.5 |
| Volume | 67,754 shares |
| Market Cap | $5.07M |
| Exchange | NCM |
Technical Analysis (INM)
Nexqual's technical model rates INM "STRONG BUY" based on 6 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 03:31 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 65.16 (neutral) |
| vs SMA50 | Above (USD 0.97) |
| MACD | 0.19 (positive) |
Analyst Ratings (INM)
Wall Street analysts rate INM "None", per Nexqual as of June 10, 2026 at 03:31 UTC.
| Consensus Rating | None |
|---|
Earnings (INM)
| Next Earnings Date | 2026-05-12 |
|---|
Source: Nexqual, June 10, 2026 at 03:31 UTC.
Financials & Fundamentals (INM)
| Total Revenue | $4.94M |
|---|---|
| Gross Margin | +34.53% |
| Operating Margin | -162.75% |
| Profit Margin | -172.17% |
| ROE | -112.65% |
| Debt / Equity | 6.1 |
| Current Ratio | 3.12 |
| Total Cash | $5.20M |
| Total Debt | $420,147 |
| Free Cash Flow | $-3.94M |
Source: Nexqual, June 10, 2026 at 03:31 UTC.
Financial Health Score (INM)
Nexqual rates Inmed Pharmaceuticals Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:31 UTC.
| Growth | Strong — Revenue +279% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $5M cash, no debt |
| Cash Flow | Weak — FCF negative: -$4M, burning cash |
| Efficiency | Critical — ROE -113%, ROA -54.6% |
Ownership (INM)
| Insider Ownership | +0.12% |
|---|---|
| Institutional Ownership | +46.01% |
| Shares Outstanding | 3.31M |
| Float | 1.38M |
| Short % of Float | +4.07% |
Source: Nexqual, June 10, 2026 at 03:31 UTC.
Leadership (INM)
Inmed Pharmaceuticals Inc. is led by Eric A. Adams B.S. Chem., M.I.B. (age 61), President, CEO & Director, per Nexqual as of June 10, 2026 at 03:31 UTC.
| President, CEO & Director | Eric A. Adams B.S. Chem., M.I.B. (age 61) |
|---|---|
| CFO & Corporate Secretary | N. Netta Jagpal (age 52) |
| Chief Operating Officer | Michael Woudenberg P.Eng. (age 55) |
| Senior Vice President of Preclinical Research & Development | Eric Chih-Hsien Hsu (age 54) |
| Vice President of Sales & Marketing | Jerry P. Griffin |
Major Backers & Investors (INM)
Notable institutional backers of Inmed Pharmaceuticals Inc. include Sabby Management, LLC, AdvisorShares Pure Cannabis ETF, Citadel, according to Nexqual as of June 10, 2026 at 03:31 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Sabby Management, LLC | 6.65% |
| AdvisorShares Pure Cannabis ETF | 2.36% |
| Citadel | 1.42% |
| Virtu Financial LLC | 0.6% |
| Two Sigma Securities, LLC | 0.56% |
| UBS Group AG | 0.24% |
| Private Wealth Management Group, LLC | 0.15% |
Source: Nexqual, June 10, 2026 at 03:31 UTC.
From Inmed Pharmaceuticals Inc.'s Latest SEC 10-K Filing (filed 2025-09-23)
Key Strengths & Strategy (as disclosed to the SEC)
- InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States.
- The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial.
- The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products.
- The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ENSC | Ensysce Biosciences, Inc. | USD 0.25 | ▲ 0% |
| NUWE | Nuwellis, Inc. | USD 0.15 | ▼ 14.71% |
| REVB | Revelation Biosciences, Inc. | USD 1.04 | ▲ 5.05% |
| PALI | Palisade Bio, Inc. | USD 1.69 | ▼ 2.87% |
| QNRX | Quoin Pharmaceuticals, Ltd. | USD 4.95 | ▲ 10.24% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:31 UTC. This page is informational and not investment advice.